Fortis Shares Upgraded To 'Buy' By ICICI Securities After Q3 Results — Check Revised Target Price

ICICI Securities has upgraded Fortis Healthcare's stock rating to 'Buy' following the release of its Q3 financial results, which demonstrated strong performance metrics. The firm projects an impressive EBITDA compound annual growth rate (CAGR) of 26.1% for the period from FY25 to FY28, underpinned by an anticipated revenue CAGR of 19.2%. This optimistic outlook reflects Fortis's strategic initiatives and operational efficiencies, positioning the company favorably in the competitive healthcare sector. The revised target price suggests significant upside potential for investors, highlighting Fortis's resilience and growth trajectory amidst a dynamic market landscape. As healthcare demands evolve, Fortis is poised to capitalize on emerging opportunities, making it an attractive investment choice for stakeholders looking to benefit from the sector's expansion.